TNDM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

276.95M

-2.02%

-0.094

-78.48%

248.80M

+6.13%

-0.418

-37.1%

266.85M

+10.87%

-0.296

-38.8%

Estimates Revision

The market is revising Downward the revenue expectations for Tandem Diabetes Care, Inc. (TNDM) for FY2025, with the revenue forecasts being adjusted by -0.11% over the past three months. During the same period, the stock price has changed by 43.90%.

Revenue Estimates for FY2025

Revise Downward

-0.11%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.77%

In Past 3 Month

Stock Price

Go Up

+43.90%

In Past 3 Month

17 Analyst Rating

Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 22.71 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

10 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

14.00

Averages

22.71

High

55.00

Current: 0.000

Low

14.00

Averages

22.71

High

55.00

Truist

Hold

maintain

$17 -> $24

2025-12-18

Reason

Truist

Price Target

$17 -> $24

2025-12-18

maintain

Hold

Reason

Truist raised the firm's price target on Tandem Diabetes to $24 from $17 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

Canaccord

William Plovanic

Buy

maintain

$24 -> $35

2025-12-17

Reason

Canaccord

William Plovanic

Price Target

$24 -> $35

2025-12-17

maintain

Buy

Reason

Canaccord analyst William Plovanic raised the firm's price target on Tandem Diabetes to $35 from $24 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.

RBC Capital

Outperform

maintain

$25 -> $30

2025-12-17

Reason

RBC Capital

Price Target

$25 -> $30

2025-12-17

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Tandem Diabetes to $30 from $25 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that it continues to benefit from Mobi adoption and has the best in-class algorithm controlling its AID systems, also stating that Tandem's global addressable market is expanding, positioning it for revenue upside.

Mizuho

Anthony Petrone

Neutral

maintain

$18 -> $21

2025-12-17

Reason

Mizuho

Anthony Petrone

Price Target

$18 -> $21

2025-12-17

maintain

Neutral

Reason

Mizuho analyst Anthony Petrone raised the firm's price target on Tandem Diabetes to $21 from $18 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion "under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector," the analyst tells investors in a research note.

Baird

Neutral -> Outperform

upgrade

$18 -> $30

2025-12-16

Reason

Baird

Price Target

$18 -> $30

2025-12-16

upgrade

Neutral -> Outperform

Reason

Baird upgraded Tandem Diabetes to Outperform from Neutral with a price target of $30, up from $18. The firm adjusted ratings and medical technology as part of its 2026 outlook. Baird cites solid end markets, the company's pharmacy revenue and margin tailwinds, and the Mobi-T mid-year launch for the upgrade of Tandem.

Citi

Neutral

maintain

$16 -> $22

2025-12-11

Reason

Citi

Price Target

$16 -> $22

2025-12-11

maintain

Neutral

Reason

Citi raised the firm's price target on Tandem Diabetes to $22 from $16 and keeps a Neutral rating on the shares. Citi also added a "downside 90-day catalyst watch" on the shares. The firm sees 2026 expectations as too high going into the company's initial outlook.

Valuation Metrics

The current forward P/E ratio for Tandem Diabetes Care Inc (TNDM.O) is -20.80, compared to its 5-year average forward P/E of 52.04. For a more detailed relative valuation and DCF analysis to assess Tandem Diabetes Care Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

52.04

Current PE

-20.80

Overvalued PE

191.59

Undervalued PE

-87.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

142.61

Current EV/EBITDA

31.43

Overvalued EV/EBITDA

373.72

Undervalued EV/EBITDA

-88.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.24

Current PS

1.36

Overvalued PS

7.45

Undervalued PS

1.03

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 870.81% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TNDM News & Events

Events Timeline

No data

News

3.5

2025-12-31PRnewswire

Avant Technologies Achieves 83% Insulin Independence Rate, Driving Investment Shift

3.5

2025-12-31Newsfilter

Avant Technologies Achieves 83% Insulin Independence Rate, Driving Metabolic Disease Investment

7.0

2025-12-31PRnewswire

Rosen Law Firm Investigates Potential Securities Claims for Tandem Diabetes Care, Inc.

People Also Watch

Frequently Asked Questions

What is Tandem Diabetes Care Inc (TNDM) stock price today?

The current price of TNDM is 22.075 USD — it has decreased -2.8 % in the last trading day.

What is Tandem Diabetes Care Inc (TNDM)'s business?

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

What is the price predicton of TNDM Stock?

What is Tandem Diabetes Care Inc (TNDM)'s revenue for the last quarter?

Tandem Diabetes Care Inc revenue for the last quarter amounts to 249.25M USD, increased 2.17 % YoY.

What is Tandem Diabetes Care Inc (TNDM)'s earnings per share (EPS) for the last quarter?

Tandem Diabetes Care Inc. EPS for the last quarter amounts to -0.31 USD, decreased -11.43 % YoY.

What changes have occurred in the market's expectations for Tandem Diabetes Care Inc (TNDM)'s fundamentals?

How many employees does Tandem Diabetes Care Inc (TNDM). have?

Tandem Diabetes Care Inc (TNDM) has 2650 emplpoyees as of January 08 2026.

What is Tandem Diabetes Care Inc (TNDM) market cap?

Today TNDM has the market capitalization of 1.54B USD.